We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The final rule defines the criteria the agency uses to determine which bulk drug substances will allowed for use in drug compounding operations. Read More
According to the report, the two WHO guidelines on treating severe pain “alarmingly” copy Purdue’s marketing strategies for increasing prescriptions and sales. Read More
America’s opioid crisis may be worsening—but there also may be a critical shortage of pain relief drugs, a government task force has concluded. Read More
A New Jersey generics maker pleaded guilty to price fixing and agreed to cooperate with an ongoing investigation into the generics industry, the Department of Justice announced Friday. Read More
CBD and THC are still regulated as prescription drugs and still illegal in food or supplements, but for now the FDA is going to focus on enforcement of false marketing claims, Acting Commissioner Ned Sharpless said Friday. Read More
The agency wants biosimilar sponsors to be ready for the 2019-2020 flu season and is urging sponsors to get their applications in by June 17. Read More
Working out of the firm’s Chevy Chase, Maryland office, Gottlieb will be involved as a full-time active investor across all the firm’s healthcare activities, with a focus on biopharmaceutical and healthcare services. Read More
“Today’s approval marks another milestone in the transformational power of gene and cell therapies to treat a wide range of diseases,” said Acting FDA Commissioner Ned Sharpless. Read More
A lower court’s dismissal of a case involving a patient’s suicide while taking generic versions of GlaxoSmithKline’s antidepressant Paxil (paroxetine) will stand, the Supreme Court has ruled. Read More